Talaris Therapeutics (Talaris Therapeutics) Cash-to-Debt : 148.39 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Talaris Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Talaris Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2023 was 148.39.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Talaris Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Talaris Therapeutics's Cash-to-Debt or its related term are showing as below:

TALS' s Cash-to-Debt Range Over the Past 10 Years
Min: 62.46 Med: 5074.2 Max: No Debt
Current: 148.39

During the past 4 years, Talaris Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 62.46. And the median was 5074.20.

TALS's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.24 vs TALS: 148.39

Talaris Therapeutics Cash-to-Debt Historical Data

The historical data trend for Talaris Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Talaris Therapeutics Cash-to-Debt Chart

Talaris Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

No Debt

62.86

Talaris Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash-to-Debt	Get a 7-Day Free Trial										63.43	62.46	62.86	130.36	148.39

Competitive Comparison of Talaris Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Talaris Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Talaris Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Talaris Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Talaris Therapeutics's Cash-to-Debt falls into.

Talaris Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Talaris Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	181.282	/	(0.91	+	1.974)
	=	62.86

Talaris Therapeutics's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	152.252	/	(0.601	+	0.425)
	=	148.39

Talaris Therapeutics (NAS:TALS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Talaris Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Talaris Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Talaris Therapeutics (Talaris Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Talaris Therapeutics Inc (NAS:TALS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

93 Worcester Street, Wellesley, MA, USA, 02481

Website

https://www.talaristx.com

Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.

Executives

Cariad Chester	director	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Yung H. Chyung	officer: Chief Medical Officer	C/O SCHOLAR ROCK, 620 MEMORIAL DR., 2ND FLOOR, CAMBRIDGE MA 02139
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
W Bradford Middlekauff	officer: CBO, GC and Secretary	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Aaron Kantoff	director	C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH
Sandeep Chidambar Kulkarni	director, officer: CEO	92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Kevin Bruce Johnson	officer: Chief Regulatory Officer	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Ryan F. Robinson	officer: Interim CFO	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Parvinder Thiara	director	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Susan Dana Jones	officer: Chief Technology Officer	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Suzanne Ildstad	director, 10 percent owner, officer: Chief Scientific Officer	C/O TALARIS THERAPEUTICS, INC., 93 WORCESTER STREET, SUITE 120, WELLESLEY MA 02481
Scott Requadt	director, officer: See Remarks	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025